Consolidation and maintenance therapy with bortezomib for Vietnamese patients with multiple myeloma after autologous transplantation.

Thirty patients with newly diagnosed symtomatic MM (multiple myeloma) received ASCT (autologous stem cell transplantation) and two cycles of bortezomib-cyclophosphamide-dexamethasone as consolidation treatment followed by maintenance of bortezomib for 24 months. 16 patients achieved complete response (CR) after ASCT, and two more patients achieved CR after consolidation therapy. At 92 months of follow-up, the median OS was 69.5 months, the median PFS was 38.5 months. OS and PFS in the high-risk group were shorter than in the standard-risk group with a statistically significant difference ( = 0.028, 0.049; respectively). Post-ASCT consolidation and maintenance therapy using bortezomib were effective in patients with MM.